<DOC>
	<DOC>NCT01529528</DOC>
	<brief_summary>This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.</brief_summary>
	<brief_title>A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 DM patients Subjects who couldn't control the blood glucose despite of a dietary and exercise therapy more than 6 weeks at screening visit FPG â‰¤ 270mg/dL at screening visit Patients who consent to participate in this trial by written Informed Consent Form Type 1 DM or secondary diabetes Subjects who are administrating insulin or need to insulin therapy History of oral antihyperglycemic drugs within 6 weeks before screening visit Body mass index &lt; 20 kg/m2 or &gt; 40.0kg/m2 Subjects who are assessed to be inappropriate for this trial by investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CWP-0403</keyword>
	<keyword>type 2 DM</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase 3</keyword>
</DOC>